AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37068366 — intervention group
Group type: COMPARATOR
Intervention: De-escalating cannabis use pattern
Number of subjects: 149
Study 37068504 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolbetuximab plus mFOLFOX6
Number of subjects: 565
Study 37068504 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus mFOLFOX6
Number of subjects: 565
Study 37068528 — intervention group
Group type: EXPERIMENTAL
Intervention: AF devices (AFX/AFX2 endograft system)
Number of subjects: 455
Study 37068528 — intervention group
Group type: COMPARATOR
Intervention: PF devices (Cook Medical Zenith Flex; Gore Excluder; Medtronic Endurant II)
Number of subjects: 455
Study 37068889 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol total intravenous anaesthesia (TIVA)
Number of subjects: 300
Study 37068889 — intervention group
Group type: COMPARATOR
Intervention: Inhaled volatile anaesthesia (INVA)
Number of subjects: 300
Study 37068892 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction of labour with oxytocin
Number of subjects: 1494
Study 37068892 — intervention group
Group type: COMPARATOR
Intervention: Repeated cervical ripening with prostaglandins (slow-release vaginal dinoprostone; oral misoprostol 25 µg; dinoprostone vaginal gel 2 mg)
Number of subjects: 1494
Study 37068892 — intervention group
Group type: COMPARATOR
Intervention: Repeated cervical ripening with prostaglandins
Number of subjects: 1494
Study 37068906 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalised AKI recommendations delivered by a physician and pharmacist team after AKI detection.
Number of subjects: 4000
Study 37068906 — intervention group
Group type: COMPARATOR
Intervention: Usual care arm (no real-time recommendations).
Number of subjects: 4000
Study 37068952 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranberry products
Number of subjects: 8857
Study 37069007 — intervention group
Group type: EXPERIMENTAL
Intervention: Holmium laser enucleation of the prostate (HoLEP)
Number of subjects: 243
Study 37069007 — intervention group
Group type: EXPERIMENTAL
Intervention: HoLEP
Number of subjects: 243
Study 37069359 — intervention group
Group type: EXPERIMENTAL
Intervention: Motixafortide and G-CSF
Number of subjects: 0
Study 37069359 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 37069364 — intervention group
Group type: EXPERIMENTAL
Intervention: SEL-037 0.2 mg/kg + SEL-110 0.1-0.15 mg/kg
Number of subjects: 152
Study 37069364 — intervention group
Group type: COMPARATOR
Intervention: SEL-037 0.2 mg/kg alone
Number of subjects: 152
Study 37069364 — intervention group
Group type: COMPARATOR
Intervention: SEL-110 withdrawn after week 12
Number of subjects: 152
Study 37069364 — intervention group
Group type: EXPERIMENTAL
Intervention: SEL-037 0.2 mg/kg + SEL-110 0.15 mg/kg
Number of subjects: 152
Study 37069364 — intervention group
Group type: EXPERIMENTAL
Intervention: SEL-110 at doses up to 0.1 mg/kg
Number of subjects: 152
Study 37069472 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-lumen needle (DLN)
Number of subjects: 200
Study 37069472 — intervention group
Group type: COMPARATOR
Intervention: Single-lumen needle (SLN)
Number of subjects: 200
Study 37069490 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 300
Study 37069490 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Activation for Smoking Cessation (BASC)
Number of subjects: 300
Study 37069490 — intervention group
Group type: COMPARATOR
Intervention: Standard Behavioral Treatment (ST)
Number of subjects: 300
Study 37069490 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study 37069510 — intervention group
Group type: EXPERIMENTAL
Intervention: Institutional adaptation of symptom management care pathways
Number of subjects: 10
Study 37069510 — intervention group
Group type: EXPERIMENTAL
Intervention: Institutional adaptation process
Number of subjects: 10
Study 37069510 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasons for rejection of statements
Number of subjects: 10
Study 37069510 — intervention group
Group type: COMPARATOR
Intervention: Institutional-level factors
Number of subjects: 10
Study 37069518 — intervention group
Group type: EXPERIMENTAL
Intervention: Children living with HIV (CLHIV)
Number of subjects: 157
Study 37069518 — intervention group
Group type: COMPARATOR
Intervention: Children without HIV
Number of subjects: 157
Study 37069527 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradialytic exercise (60 min during the second hour of thrice weekly dialysis for 6 months)
Number of subjects: 74
Study 37069527 — intervention group
Group type: COMPARATOR
Intervention: No intradialytic exercise (control)
Number of subjects: 74
Study 37069527 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradialytic exercise
Number of subjects: 74
Study 37069531 — intervention group
Group type: EXPERIMENTAL
Intervention: gCJD patients
Number of subjects: 0
Study 37069531 — intervention group
Group type: COMPARATOR
Intervention: Healthy relatives (HR)
Number of subjects: 0
Study 37069593 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical social worker
Number of subjects: 19
Study 37069593 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer recovery specialist
Number of subjects: 19
Study 37069593 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 19
Study 37069599 — intervention group
Group type: EXPERIMENTAL
Intervention: Back School intervention (8-week program, 2 sessions per week, 16 sessions total, 45 min each)
Number of subjects: 58
Study 37069599 — intervention group
Group type: EXPERIMENTAL
Intervention: Back School intervention
Number of subjects: 58
Study 37069599 — intervention group
Group type: COMPARATOR
Intervention: Control group (no lifestyle changes)
Number of subjects: 58
Study 37069599 — intervention group
Group type: COMPARATOR
Intervention: Comparison between EG and CG
Number of subjects: 58
Study 37069685 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantra QPlus System
Number of subjects: 128
Study 37069970 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 5 mg or 15 mg (doses pooled for analyses)
Number of subjects: 0
Study 37069970 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 37070017 — intervention group
Group type: EXPERIMENTAL
Intervention: MARIGOLD (Mobile Affect Regulation Intervention with the Goal of Lowering Depression)
Number of subjects: 0
Study 37070017 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 37070261 — intervention group
Group type: EXPERIMENTAL
Intervention: Thinking for a Change intervention
Number of subjects: 47
Study 37070261 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 47
Study 37070436 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin (10 mg once daily for 12 weeks)
Number of subjects: 72
Study 37070436 — intervention group
Group type: COMPARATOR
Intervention: Placebo (once daily for 12 weeks)
Number of subjects: 72
Study 37070473 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban
Number of subjects: 0
Study 37070473 — intervention group
Group type: COMPARATOR
Intervention: Warfarin (vitamin K antagonist)
Number of subjects: 0
Study 37070491 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation-based teaching
Number of subjects: 324
Study 37070491 — intervention group
Group type: COMPARATOR
Intervention: Traditional teaching
Number of subjects: 324
Study 37070556 — intervention group
Group type: EXPERIMENTAL
Intervention: Long cART exposure (cART initiation preconception)
Number of subjects: 44
Study 37070556 — intervention group
Group type: COMPARATOR
Intervention: HIV-unexposed-children (HUU)
Number of subjects: 44
Study 37070556 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased methionine-sulfone levels in children
Number of subjects: 44
Study 37070653 — intervention group
Group type: EXPERIMENTAL
Intervention: Camizestrant
Number of subjects: 0
Study 37070653 — intervention group
Group type: COMPARATOR
Intervention: Aromatase inhibitor + CDK4/6 inhibitor
Number of subjects: 0
Study 37070660 — intervention group
Group type: COMPARATOR
Intervention: PFMT plus biofeedback
Number of subjects: 3079
Study 37070660 — intervention group
Group type: COMPARATOR
Intervention: Combinations of conservative treatments
Number of subjects: 3079
Study 37070660 — intervention group
Group type: COMPARATOR
Intervention: Electrical or magnetic stimulation
Number of subjects: 3079
Study 37070673 — intervention group
Group type: COMPARATOR
Intervention: Living in extreme poverty (defined as below 120% of federal poverty thresholds) during ALL maintenance therapy.
Number of subjects: 592
Study 37070673 — intervention group
Group type: EXPERIMENTAL
Intervention: Not living in extreme poverty (above 120% of federal poverty thresholds) during ALL maintenance therapy.
Number of subjects: 592
Study 37070673 — intervention group
Group type: EXPERIMENTAL
Intervention: Children living in extreme poverty (nonadherence to mercaptopurine).
Number of subjects: 592
Study 37070673 — intervention group
Group type: COMPARATOR
Intervention: Children not living in extreme poverty (nonadherence to mercaptopurine).
Number of subjects: 592
Study 37070673 — intervention group
Group type: EXPERIMENTAL
Intervention: Children living in extreme poverty (hazard of relapse).
Number of subjects: 592
Study 37070715 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatic exercises + Pain Neuroscience Education (PNE)
Number of subjects: 75
Study 37070715 — intervention group
Group type: COMPARATOR
Intervention: Aquatic exercises (AEG)
Number of subjects: 75
Study 37070830 — intervention group
Group type: EXPERIMENTAL
Intervention: Secretory-IgA (SIgA) binding to intestinal microbiota
Number of subjects: 0
Study 37070830 — intervention group
Group type: EXPERIMENTAL
Intervention: SIgA affinity to the microbiota
Number of subjects: 0
Study 37070852 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelacarsen
Number of subjects: 0
Study 37070852 — intervention group
Group type: EXPERIMENTAL
Intervention: Olpasiran
Number of subjects: 0
Study 37070852 — intervention group
Group type: EXPERIMENTAL
Intervention: SLN360
Number of subjects: 0
Study 37070852 — intervention group
Group type: EXPERIMENTAL
Intervention: LY3819469
Number of subjects: 0
Study 37070854 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical features, NCCT radiological features, and radiomic features
Number of subjects: 317
Study 37070854 — intervention group
Group type: EXPERIMENTAL
Intervention: NCCT radiological features
Number of subjects: 317
Study 37070854 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical & radiomic combination model
Number of subjects: 317
Study 37070854 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of radiomics features
Number of subjects: 317
Study 37070854 — intervention group
Group type: EXPERIMENTAL
Intervention: NCCT radiological signs
Number of subjects: 317
Study 37070854 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiomic features
Number of subjects: 317
Study 37071035 — intervention group
Group type: EXPERIMENTAL
Intervention: HD incorporating 30 minutes of aerobic exercise (HDEX)
Number of subjects: 60
Study 37071035 — intervention group
Group type: COMPARATOR
Intervention: Standard HD
Number of subjects: 60
Study 37071038 — intervention group
Group type: EXPERIMENTAL
Intervention: Guselkumab
Number of subjects: 0
Study 37071038 — intervention group
Group type: COMPARATOR
Intervention: Ustekinumab
Number of subjects: 0
Study 37071038 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab→Guselkumab
Number of subjects: 0
Study 37071094 — intervention group
Group type: EXPERIMENTAL
Intervention: Panitumumab
Number of subjects: 823
Study 37071094 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab
Number of subjects: 823
Study 37071112 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoballoon ablation (CBA)
Number of subjects: 2709
Study 37071166 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (0.7 mL/kg iohexol 350 mgI/mL)
Number of subjects: 212
Study 37071166 — intervention group
Group type: COMPARATOR
Intervention: Control group (1.4 mL/kg iohexol 350 mgI/mL)
Number of subjects: 212
Study 37071285 — intervention group
Group type: EXPERIMENTAL
Intervention: FMS + OSAS
Number of subjects: 69
Study 37071285 — intervention group
Group type: COMPARATOR
Intervention: OSAS only
Number of subjects: 69
Study 37071317 — intervention group
Group type: COMPARATOR
Intervention: Expert opinion elicitation in Bayesian analysis
Number of subjects: 0
Study 37071317 — intervention group
Group type: COMPARATOR
Intervention: Bayesian analysis using expert opinion
Number of subjects: 0
Study 37071469 — intervention group
Group type: EXPERIMENTAL
Intervention: L-ficolin, hyaluronic acid (HA), and stimulation 2 (ST2) measured on day 3 after HCT
Number of subjects: 80
Study 37071469 — intervention group
Group type: EXPERIMENTAL
Intervention: Low L-ficolin levels
Number of subjects: 80
Study 37071469 — intervention group
Group type: EXPERIMENTAL
Intervention: High HA levels
Number of subjects: 80
Study 37071469 — intervention group
Group type: EXPERIMENTAL
Intervention: High ST2 levels
Number of subjects: 80
Study 37071469 — intervention group
Group type: EXPERIMENTAL
Intervention: L-ficolin levels
Number of subjects: 80
Study 37071469 — intervention group
Group type: EXPERIMENTAL
Intervention: HA levels
Number of subjects: 80
Study 37071469 — intervention group
Group type: EXPERIMENTAL
Intervention: ST2 levels
Number of subjects: 80
Study 37071612 — intervention group
Group type: EXPERIMENTAL
Intervention: eHealth Familias Unidas Mental Health intervention
Number of subjects: 468
Study 37071764 — intervention group
Group type: EXPERIMENTAL
Intervention: Apalutamide combined with abiraterone and prednisone
Number of subjects: 972
Study 37071764 — intervention group
Group type: COMPARATOR
Intervention: Placebo combined with abiraterone and prednisone
Number of subjects: 972
Study 37071834 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin combination chemotherapy
Number of subjects: 4748
Study 37071834 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity at diagnosis
Number of subjects: 4748
Study 37071834 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking at diagnosis
Number of subjects: 4748
Study 37071834 — intervention group
Group type: EXPERIMENTAL
Intervention: Raynaud's phenomenon
Number of subjects: 4748
Study 37071834 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyslipidemia
Number of subjects: 4748
Study 37071834 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive family history for CVD
Number of subjects: 4748
Study 37071834 — intervention group
Group type: EXPERIMENTAL
Intervention: CVD in TC survivors
Number of subjects: 4748
Study 37071834 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical evaluation for cardiovascular risk factors
Number of subjects: 4748
Study 37071836 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous rituximab
Number of subjects: 202
Study 37071836 — intervention group
Group type: COMPARATOR
Intervention: Watch and wait strategy (control)
Number of subjects: 202
Study 37071838 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab first-line maintenance therapy
Number of subjects: 0
Study 37071838 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 37072105 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD4831 5 mg
Number of subjects: 41
Study 37072105 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 37072143 — intervention group
Group type: EXPERIMENTAL
Intervention: Early reconstruction with sepsis control (Group B)
Number of subjects: 277
Study 37072143 — intervention group
Group type: EXPERIMENTAL
Intervention: Early reconstruction without sepsis control (Group A)
Number of subjects: 277
Study 37072143 — intervention group
Group type: COMPARATOR
Intervention: Delayed reconstruction (Group C)
Number of subjects: 277
Study 37072180 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-POEM (13 cm)
Number of subjects: 200
Study 37072180 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-POEM (8 cm)
Number of subjects: 200
Study 37072219 — intervention group
Group type: EXPERIMENTAL
Intervention: Symbol Digit Modalities Test (SDMT)
Number of subjects: 1814
Study 37072219 — intervention group
Group type: EXPERIMENTAL
Intervention: Paced Auditory Serial Addition Test (PASAT)
Number of subjects: 1814
Study 37072219 — intervention group
Group type: COMPARATOR
Intervention: Timed 25-foot walk (T25FW)
Number of subjects: 1814
Study 37072346 — intervention group
Group type: EXPERIMENTAL
Intervention: CD45RA-depleted PBMCs (RAD-PBMCs)
Number of subjects: 0
Study 37072346 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated whole PBMCs (W-PBMCs)
Number of subjects: 0
Study 37072346 — intervention group
Group type: COMPARATOR
Intervention: Naïve T-cell fraction
Number of subjects: 0
Study 37072346 — intervention group
Group type: COMPARATOR
Intervention: CD45RA+ regulatory T cells, natural killer cells, stem cell memory, and effector memory subsets
Number of subjects: 0
Study 37072346 — intervention group
Group type: EXPERIMENTAL
Intervention: CD45RA depletion of PBMCs from patients with lymphoma
Number of subjects: 0
Study 37072349 — intervention group
Group type: EXPERIMENTAL
Intervention: Polio virotherapy with prior polio vaccination
Number of subjects: 2
Study 37072349 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratumor recall of poliovirus or tetanus immunity
Number of subjects: 2
Study 37072349 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratumor recall antigens
Number of subjects: 2
Study 37072361 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate once-monthly (PP1M)
Number of subjects: 33
Study 37072361 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate once-every-3-months (PP3M)
Number of subjects: 33
Study 37072361 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (oral run-in)
Number of subjects: 33
Study 37072364 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial intelligence system using physiological signals from wearable sensors (ECG and continuous glucose monitor)
Number of subjects: 30
Study 37072421 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax plus obinutuzumab (Ven-Obi)
Number of subjects: 432
Study 37072421 — intervention group
Group type: COMPARATOR
Intervention: Chlorambucil plus obinutuzumab (Clb-Obi)
Number of subjects: 432
Study 37072512 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 37072571 — intervention group
Group type: EXPERIMENTAL
Intervention: Sapanisertib with carboplatin and paclitaxel
Number of subjects: 17
Study 37072577 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg/day
Number of subjects: 60
Study 37072577 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride 4 mg/day
Number of subjects: 60
Study 37072603 — intervention group
Group type: EXPERIMENTAL
Intervention: Photobiomodulation therapy (PBMT) with gallium-aluminum-arsenide (GaAlAs) diode laser (810 nm, continuous-wave mode, 1000 mW, 0.28 cm)
Number of subjects: 22
Study 37072603 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 22
Study 37072607 — intervention group
Group type: EXPERIMENTAL
Intervention: Repository Corticotropin Injection (RCI, 80 U, subcutaneous, twice weekly for 24 weeks)
Number of subjects: 55
Study 37072607 — intervention group
Group type: EXPERIMENTAL
Intervention: Repository Corticotropin Injection (RCI)
Number of subjects: 55
Study 37072607 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 37072730 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated pulsed high-fluence corneal cross-linking (pl-ACXL, 30 mW/cm²)
Number of subjects: 27
Study 37072737 — intervention group
Group type: EXPERIMENTAL
Intervention: EMI
Number of subjects: 525
Study 37072737 — intervention group
Group type: EXPERIMENTAL
Intervention: EMI + Virtual Home Visiting with CHW + Video Feedback
Number of subjects: 525
Study 37072737 — intervention group
Group type: EXPERIMENTAL
Intervention: EMI + Hybrid Home Visiting with CHW + Video Feedback
Number of subjects: 525
Study 37072778 — intervention group
Group type: EXPERIMENTAL
Intervention: Feverkidstool
Number of subjects: 8211
Study 37072778 — intervention group
Group type: EXPERIMENTAL
Intervention: Craig model
Number of subjects: 8211
Study 37072778 — intervention group
Group type: EXPERIMENTAL
Intervention: SBI score
Number of subjects: 8211
Study 37072778 — intervention group
Group type: EXPERIMENTAL
Intervention: PAWS
Number of subjects: 8211
Study 37072812 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-week specialized low-intensity rehabilitation program, including exercise and respiratory therapy and mental gait training
Number of subjects: 90
Study 37072812 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 90
Study 37072843 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole
Number of subjects: 45
Study 37072843 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphotericin B
Number of subjects: 45
Study 37072843 — intervention group
Group type: EXPERIMENTAL
Intervention: Anidulafungin
Number of subjects: 45
Study 37072843 — intervention group
Group type: EXPERIMENTAL
Intervention: Nystatin
Number of subjects: 45
Study 37072843 — intervention group
Group type: EXPERIMENTAL
Intervention: C. albicans
Number of subjects: 45
Study 37072843 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-C. albicans species
Number of subjects: 45
Study 37073174 — intervention group
Group type: EXPERIMENTAL
Intervention: Training adaptation intervention, details not specified.
Number of subjects: 0
Study 37073174 — intervention group
Group type: COMPARATOR
Intervention: Control group advised to reduce intensity and amount of training, details not specified.
Number of subjects: 0
Study 37073421 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (prophylactic, dosage not specified)
Number of subjects: 2296
Study 37073442 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine and bupivacaine (100 μg morphine and 15 mg bupivacaine)
Number of subjects: 96
Study 37073442 — intervention group
Group type: COMPARATOR
Intervention: Control group (nonspinal group)
Number of subjects: 96
Study 37073512 — intervention group
Group type: EXPERIMENTAL
Intervention: GORE VIABAHN VBX Balloon Expandable Endoprosthesis
Number of subjects: 59
Study 37073741 — intervention group
Group type: EXPERIMENTAL
Intervention: Vincristine/irinotecan/temsirolimus (VIT)
Number of subjects: 36
Study 37073741 — intervention group
Group type: COMPARATOR
Intervention: Vincristine/irinotecan (VI) alone
Number of subjects: 36
Study 37073753 — intervention group
Group type: EXPERIMENTAL
Intervention: Offline anosognosia rehabilitation
Number of subjects: 0
Study 37073753 — intervention group
Group type: COMPARATOR
Intervention: Standard neglect rehabilitation
Number of subjects: 0
Study 37073794 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib
Number of subjects: 0